PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

Description: PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

Summary

Meningococcal disease is an acute infection caused by the bacterium Neisseria meningitidis, an aerobic, gram-negative diplococcal microbe that is only pathogenic in humans. Different N. meningitides strains are typically classified into serotypes based on the structure of the polysaccharide capsule surrounding the outer membrane, with five serotypes (A, B, C, W-135, and Y) being responsible for the majority of invasive infections. The meningococci are spread primarily by the exchange of bodily fluids (i.e. saliva) and enter the body by attaching to the epithelial cells of the nasopharynx. Upon adhesion, the bacteria then begin to proliferate and form micro-colonies on the surface of the epithelial cells. Symptoms of systemic infection develop rapidly and include flu-like symptoms (headache, fever, sore throat, nausea, and vomiting), sensitivity to light, and a stiff neck. If left untreated, meningococcal disease progresses rapidly and is often fatal, and a significant population of survivors (10-20%) are left with complications such as loss of a limb, deafness, epilepsy, and mental retardation. Due to the rapid onset and severity of symptoms, vaccination remains the preferred approach to meningococcal disease management and prevention. Currently available vaccines protect against all serotypes A, B, C, W-135, and Y and utilize the polysaccharide as antigens although no single vaccine can protect against all serogroups simultaneously. GlobalData expects growth in the meningococcal vaccines market to be driven by the recent launch of serotype B vaccines, which address a critical unmet need in the treatment landscape, and an increase in the coverage rates of existing routine vaccination programs.

Highlights

Key Questions Answered

- Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the meningococcal vaccine marketplace.
- What will be the effect of recent acquisitions be on the meningococcal vaccine marketplace?
- How will the new first-in class-vaccines against serogroup B be received in the different markets?
- What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
- Which patient population(s) are most likely to be targeted for vaccines against serogroup B?

Key Findings

- GlobalData projects the meningococcal vaccine market in the US, 5EU, Brazil and Australia to grow from approximately $1.1bn in 2012 to $1.5bn in 2022, at a compound annual growth rate (CAGR) of 3.0%. This growth across the 8MM will primarily be driven by the 5EU due to implementation of serogroup B vaccines in the routine infant vaccination schedule. Further growth will be the result of adolescents, including college students, in US receiving the newly approved vaccines against serogroup B while the commercial meningococcal vaccine market in Brazil will experience a decline at a negative CAGR of 16.3%.
- With full implementation of serogroup B vaccines only realized in the UK, the routine application of these vaccines is seen as the major unmet need to be addressed in the oncoming years.
- GlobalData anticipates that opportunities will center on the improvement of vaccine efficacy, in particular in the emerging field of vaccines against serogroup B whilst addressing the cost effectiveness concerns voiced by various governmental institutions.

Scope

- Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, regional serogroup distribution as well current meningococcal vaccine recommendation of all 8MM covered.
- Topline meningococcal vaccine market revenue from 2012-2022. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the meningococcal vaccine market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

Analysis of the current and future market competition in the global meningococcal vaccine market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global genital herpes market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the genital herpes market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.2.1 Infants and Young Children are at Greatest Risk for Developing Meningococcal Disease
4.2.2 Direct Contact and Overcrowding are the Primary Risk Factors for Infection
4.2.3 Exposure is Highest for Those Traveling to the African “Meningitis Belt”
4.3 Global Trends
4.3.1 US
4.3.2 5EU
4.3.3 Australia
4.3.4 Brazil

4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used

4.5 Epidemiology Forecast of Meningococcal Disease (2012-2022)
4.5.1 Incident Cases of Meningococcal Disease
4.5.2 Age-Specific Incident Cases of Meningococcal Disease
4.5.3 Incident Cases of Meningococcal Disease by Serogroup

4.6 Discussion
4.6.1 Conclusions on Epidemiological Trends
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis

5 Disease Management
5.1 Meningococcal Immunization Policy
5.2 US
5.2.1 Meningococcal Immunization Recommendations and Policies
5.2.2 Clinical Practice
5.3 France
5.3.1 Meningococcal Immunization Recommendations and Policies
5.3.2 Clinical Practice
5.4 Germany
5.4.1 Meningococcal Immunization Recommendations and Policies
5.4.2 Clinical Practice
5.5 Italy
5.5.1 Meningococcal Immunization Recommendations and Policies
5.5.2 Clinical Practice
5.6 Spain
5.6.1 Meningococcal Immunization Recommendations and Policies
5.6.2 Clinical Practice
5.7 UK
5.7.1 Meningococcal Immunization Recommendations and Policies
5.7.2 Clinical Practice
5.8 Japan
5.8.1 Meningococcal Immunization Recommendations and Policies
5.8.2 Clinical Practice
5.9 Australia
5.9.1 Meningococcal Immunization Recommendations and Policies
5.9.2 Clinical Practice
5.10 Brazil
5.10.1 Meningococcal Immunization Recommendations and Policies
5.10.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Product Profiles - Serogroup A,C,W,Y vaccines
6.3.1 Menactra
6.3.2 Menveo
6.3.3 Nimenrix
6.3.4 Menomune
6.4 Product Profiles - Serogroup B Vaccines
6.4.1 Bexsero
6.4.2 Trumenba
6.5 Product Profiles - Serogroup C Vaccines
6.5.1 Meningitec
6.5.2 Menjugate
6.5.3 NeisVac-C
6.5.4 Menitorix
6.5.5 MenHibrix
7 Opportunity and Unmet Need
7.1 Overview

7.2 Unmet Needs

7.2.1 Unmet Need: Protection Against Serogroup B Disease

7.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine

7.2.3 Unmet Need: More Cost-Effective Vaccines

7.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents

7.2.5 Unmet Need: Immunogenic Infant Vaccines

7.2.6 Unmet Need: Improved Vaccination Coverage Rates

7.2.7 Unmet Need: Increased Patient Awareness and Education

7.3 Unmet Needs Gap Analysis

7.4 Opportunities

7.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations

7.4.2 Opportunity: Improving Immune Response Duration with Adjuvants

7.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets

7.4.4 Opportunity: Reducing the Overall Vaccination Burden by Combining Meningococcal Vaccine with Other Routine Vaccinations

8 Pipeline Assessment

8.1 Overview

8.2 Clinical Trials Mapping

8.2.1 Clinical Trials by Country

8.2.2 Clinical Trials by Phase and Trial Status

8.3 Promising Vaccines in Clinical Development

8.3.1 Meninge ACYW conj.

8.3.2 MenABCWY

8.3.3 MenC Conjugate

8.3.4 Heptavalent DTP-Hib-HepB-IPV-MenC

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles

9.3.1 Sanofi
9.3.2 Pfizer
9.3.3 GlaxoSmithKline
9.4 Former Players
  9.4.1 Novartis
  9.4.2 Baxter
  9.4.3 Nuron Biotech
10 Market Outlook
  10.1 Global Markets
    10.1.1 Forecast
    10.1.2 Drivers and Barriers - Global Issues
  10.2 United States
    10.2.1 Forecast
    10.2.2 Key Events
    10.2.3 Drivers and Barriers
  10.3 France
    10.3.1 Forecast
    10.3.2 Key Events
    10.3.3 Drivers and Barriers
  10.4 Germany
    10.4.1 Forecast
    10.4.2 Key Events
    10.4.3 Drivers and Barriers
  10.5 Italy
    10.5.1 Forecast
    10.5.2 Key Events
    10.5.3 Drivers and Barriers
  10.6 Spain
    10.6.1 Forecast
    10.6.2 Key Events
    10.6.3 Drivers and Barriers
  10.7 United Kingdom
    10.7.1 Forecast
11.6.6 Global Head of Healthcare

11.7 About Us

11.8 Disclaimer

1.1 List of Tables

Table 1: Symptoms of Meningococcal Disease

Table 2: Risk Factors for Meningococcal Disease

Table 3: Sources of Incidence Data Used in the Epidemiology Forecast

Table 4: 8MM, Incident Cases of Meningococcal Disease, N, Select Years, 2012-2022

Table 5: 8MM, Incident Cases of Meningococcal Disease, By Age, N (Row %), 2012

Table 6: 8MM, Incident Cases of Meningococcal Disease, By Serogroup, N (Row %), 2012

Table 7: Meningococcal Immunization Recommendation Agencies by Country

Table 8: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2015

Table 9: Leading Vaccines for Meningococcal Disease, 2012

Table 10: Product Profile - Menactra

Table 11: Menactra SWOT Analysis, 2012

Table 12: Global Sales Forecasts ($m) for Menactra, 2012-2022

Table 13: Product Profile - Menveo

Table 14: Menveo SWOT Analysis, 2012

Table 15: Global Sales Forecasts ($m) for Menveo, 2012-2022

Table 16: Product Profile - Nimenrix

Table 17: Nimenrix SWOT Analysis, 2012

Table 18: Global Sales Forecasts ($m) for Nimenrix, 2012-2022

Table 19: Product Profile - Menomune

Table 20: Menomune SWOT Analysis, 2012

Table 21: Global Sales Forecasts ($m) for Menomune, 2012-2022

Table 22: Product Profile - Bexsero

Table 23: Bexsero SWOT Analysis, 2015

Table 24: Global Sales Forecasts ($m) for Bexsero, 2012-2022

Table 25: Product Profile - Trumenba

Table 26: Trumenba SWOT Analysis, 2015

Table 27: Global Sales Forecasts ($m) for Trumenba, 2012-2022
Table 28: Product Profile - Meningitec
Table 29: Meningitec SWOT Analysis, 2012
Table 30: Global Sales Forecasts ($m) for Meningitec, 2012-2022
Table 31: Product Profile - Menjugate
Table 32: Menjugate SWOT Analysis, 2012
Table 33: Global Sales Forecasts ($m) for Menjugate, 2012-2022
Table 34: Product Profile - NeisVac-C
Table 35: NeisVac-C SWOT Analysis, 2012
Table 36: Global Sales Forecasts ($m) for NeisVac-C, 2012-2022
Table 37: Product Profile - Menitorix
Table 38: Menitorix SWOT Analysis, 2012
Table 39: Global Sales Forecasts ($m) for Menitorix, 2012-2022
Table 40: Product Profile - MenHibrix
Table 41: MenHibrix SWOT Analysis, 2012
Table 42: Global Sales Forecasts ($m) for MenHibrix, 2012-2022
Table 43: Overall Unmet Needs - Current Level of Attainment
Table 44: Clinical Unmet Needs - Gap Analysis, 2012
Table 45: Meningococcal Vaccines - Clinical Trials by Phase and Status, 2012
Table 46: Meningococcal Vaccines - Phase Pipeline, 2012
Table 47: Comparison of Vaccines in Development for Meningococcal Disease, 2015
Table 48: Product Profile - Meninge ACYW conj.
Table 49: Meninge ACYW conj. SWOT Analysis, 2015
Table 50: Product Profile - MenABCWY
Table 51: MenABCWY SWOT Analysis, 2015
Table 52: Product Profile - MenC conjugate
Table 53: MenC conjugate SWOT Analysis, 2012
Table 54: Product Profile - Heptavalent DTP-Hib-HepB-IPV-MenC
Table 56: Key Companies in the Meningococcal Vaccines Market, 2015
Table 57: Sanofi's Meningococcal Vaccines Portfolio Assessment, 2015
Table 58: Sanofi SWOT Analysis, 2015
Table 59: Pfizer's Meningococcal Vaccines Portfolio Assessment, 2015
Table 60: Pfizer SWOT Analysis, 2015
Table 61: GSK's Meningococcal Vaccines Portfolio Assessment, 2015
Table 62: GSK SWOT Analysis, 2015
Table 63: Global Sales Forecasts ($m) for Meningococcal Vaccines, 2012-2022
Table 64: Global Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 65: Sales Forecasts ($m) for Meningococcal Vaccines in the United States, 2012-2022
Table 66: Key Events Impacting Sales for Meningococcal Vaccines in US, 2012-2022
Table 67: United States Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 68: Sales Forecasts ($m) for Meningococcal Vaccines in France, 2012-2022
Table 69: Key Events Impacting Sales for Meningococcal Vaccines in France, 2012-2022
Table 70: France Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 71: Sales Forecasts ($m) for Meningococcal Vaccines in Germany, 2012-2022
Table 72: Key Events Impacting Sales for Meningococcal Vaccines in Germany, 2012-2022
Table 73: Germany Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 74: Sales Forecasts ($m) for Meningococcal Vaccines in Italy, 2012-2022
Table 75: Key Events Impacting Sales for Meningococcal Vaccines in Italy, 2012-2022
Table 76: Italy Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 77: Sales Forecasts ($m) for Meningococcal Vaccines in Spain, 2012-2022
Table 78: Key Events Impacting Sales for Meningococcal Vaccines in Spain, 2012-2022
Table 79: Spain Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 80: Sales Forecasts ($m) for Meningococcal Vaccines in the United Kingdom, 2012-2022
Table 81: Key Events Impacting Sales for Meningococcal Vaccines in UK, 2012-2022
Table 82: United Kingdom Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 83: Japan Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 84: Sales Forecasts ($m) for Meningococcal Vaccines in Australia, 2012-2022
Table 85: Key Events Impacting Sales for Meningococcal Vaccines in Australia, 2012-2022
Table 86: Australia Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 87: Sales Forecasts ($m) for Meningococcal Vaccines in Brazil, 2012-2022
Table 88: Key Events Impacting Sales for Meningococcal Vaccines in Brazil, 2012-2022
Table 89: Brazil Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 90: Key Launch Dates
Table 91: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: Membrane Structure of N. meningitidis

Figure 2: 8MM, Incident Cases of Meningococcal Disease, N, Select Years, 2012-2022

Figure 3: 8MM, Incident Cases of Meningococcal Disease, By Age, N, 2012

Figure 4: 8MM, Incident Cases of Meningococcal Disease, By Serogroup, %, 2012

Figure 5: Meningococcal Vaccines - Clinical Trials by Country, 2012

Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012-2022

Figure 7: Company Portfolio Gap Analysis in Meningococcal Vaccines, 2012-2022

Figure 8: Global Sales for Meningococcal Vaccines by Region, 2012-2022

Figure 9: Sales for Meningococcal Vaccines in the United States by Vaccine Class, 2012-2022

Figure 10: Sales for Meningococcal Vaccines in France by Vaccine Class, 2012-2022

Figure 11: Sales for Meningococcal Vaccines in Germany by Vaccine Class, 2012-2022

Figure 12: Sales for Meningococcal Vaccines in Italy by Vaccine Class, 2012-2022

Figure 13: Sales for Meningococcal Vaccines in Spain by Vaccine Class, 2012-2022

Figure 14: Sales for Meningococcal Vaccines in the United Kingdom by Vaccine Class, 2012-2022

Figure 15: Sales for Meningococcal Vaccines in Australia by Vaccine Class, 2012-2022

Figure 16: Sales for Meningococcal Vaccines in Brazil by Vaccine Class, 2012-2022

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3622921/](http://www.researchandmarkets.com/reports/3622921/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/3622921/
Office Code: SC6I5RNI

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 10995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 21990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 32985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Select] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World